At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNTX Context Therapeutics Inc.
Market Closed 06-26 16:00:00 EDT
0.5800
+0.0200
+3.57%
盘后0.5896
+0.0096+1.66%
19:55 EDT
High0.6179Low0.5600Vol14.82M
Open0.5650D1 Closing0.5600Amplitude10.34%
Mkt Cap53.29MTradable Cap23.13MTotal Shares91.88M
T/O8.66MT/O Rate37.16%Tradable Shares39.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Context Therapeutics Shareholders Approve Increase in Authorized Common Shares to 300 Million
Reuters  ·  06-27 04:08
Context Therapeutics Shareholders Approve Increase in Authorized Common Shares to 300 Million
Context Therapeutics selloff brings buying opportunity, says JonesResearch
TIPRANKS  ·  06-16
Context Therapeutics selloff brings buying opportunity, says JonesResearch
Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX)
TIPRANKS  ·  06-16
Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX)
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
TIPRANKS  ·  06-16
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
TIPRANKS  ·  06-15
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
TIPRANKS  ·  06-15
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
Context Therapeutics reports 29% response rate in Phase 1 trial of CTIM-76 for platinum-resistant ovarian cancer
Reuters  ·  06-15
Context Therapeutics reports 29% response rate in Phase 1 trial of CTIM-76 for platinum-resistant ovarian cancer
Context Therapeutics Announces Positive Interim Efficacy and Safety Results From Ongoing Phase 1 Clinical Trial for Ctim-76
THOMSON REUTERS  ·  06-15
Context Therapeutics Announces Positive Interim Efficacy and Safety Results From Ongoing Phase 1 Clinical Trial for Ctim-76
Context Therapeutics - Ctim-76 Granted FDA Fast Track Designation in Proc
THOMSON REUTERS  ·  06-15
Context Therapeutics - Ctim-76 Granted FDA Fast Track Designation in Proc
Context Therapeutics - Reports 29% Confirmed Overall Response Rate in Proc Patients With Median 7 Prior Therapies
THOMSON REUTERS  ·  06-15
Context Therapeutics - Reports 29% Confirmed Overall Response Rate in Proc Patients With Median 7 Prior Therapies
Context Therapeutics grants new hire stock options for 146,000 shares at USD 1.71 each
Reuters  ·  06-10
Context Therapeutics grants new hire stock options for 146,000 shares at USD 1.71 each
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-10
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  06-10
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics grants new hire stock options for 146,000 shares at USD 2.63 each
Reuters  ·  05-27
Context Therapeutics grants new hire stock options for 146,000 shares at USD 2.63 each
Context Therapeutics Decline Means Insider Profits Down To US$237k
Simply Wall St.  ·  05-19
Context Therapeutics Decline Means Insider Profits Down To US$237k
Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)
TIPRANKS  ·  05-19
Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)
Context Therapeutics Secures Full Rights to Antibody Assets
TIPRANKS  ·  05-18
Context Therapeutics Secures Full Rights to Antibody Assets
Context Therapeutics enters license agreement amendment with BioAtla
TIPRANKS  ·  05-18
Context Therapeutics enters license agreement amendment with BioAtla
Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties
Reuters  ·  05-18
Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties
Context Therapeutics Enters Into License Agreement Amendment With Bioatla for Ct-202
THOMSON REUTERS  ·  05-18
Context Therapeutics Enters Into License Agreement Amendment With Bioatla for Ct-202

Introduction

Company Name.
Context Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Issue price:
--